Kiora Pharmaceuticals (KPRX)
(Delayed Data from NSDQ)
$4.23 USD
0.00 (0.00%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $4.18 -0.05 (-1.18%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
KPRX 4.23 0.00(0.00%)
Will KPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KPRX
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
KPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KPRX
Kiora Pharmaceuticals Inc trading halted, news pending
12 Health Care Stocks Moving In Thursday's After-Market Session
Buy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial Data
Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024